High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia (vol 135, pg 866, 2020)

被引：0
|
作者：
Al-Sawaf, O.
Lilienweiss, E.
Bahlo, J.
机构：
来源：
BLOOD | 2022年 / 139卷 / 25期
关键词：
D O I：
10.1182/blood.2022015745
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3669 / 3669
页数：1
相关论文
共 50 条
  • [41] Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia
    Kreuzer, Karl-Anton
    Furman, Richard R.
    Stilgenbauer, Stephan
    Dubowy, Ronald L.
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweiss, Esther
    Reinhardt, Hans Christian
    Pettitt, Andrew R.
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [42] PHARMACOECONOMIC ANALISYS OF OBINUTUZUMAB PLUS CHLORAMBUCIL IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA AND COEXISTING CONDITIONS
    Kolbin, A.
    Vilum, I
    Balykina, Y.
    Proskurin, M.
    VALUE IN HEALTH, 2017, 20 (09) : A438 - A438
  • [43] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB VERSUS IBRUTINIB IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Vieira, F. M.
    Ribeiro, G. N.
    Brito Filho, C.
    Travassos, A.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [44] ECONOMIC IMPACT OF FIXED-TREATMENT DURATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA: BUDGETIMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB FOR FIRST LINE TREATMENT OF UNFIT PATIENTS IN FRANCE
    Leblond, V
    Souihi, C.
    Ramier, J.
    Manzoor, B.
    Lepretre, S.
    VALUE IN HEALTH, 2023, 26 (12) : S185 - S185
  • [45] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Freise, Kevin J.
    Jones, Aksana K.
    Eckert, Doerthe
    Mensing, Sven
    Wong, Shekman L.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 515 - 523
  • [46] Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab
    Kreuzer, Karl-Anton
    Furman, Richard
    Stilgenbauer, Stephan
    Dubowy, Ronald
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweisz, Esther
    Reinhardt, Hans Christian
    Cramer, Paula
    Eichhorst, Barbara
    Hillmen, Peter
    O'Brien, Susan
    Pettitt, Andrew
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 : 167 - 168
  • [47] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kevin J. Freise
    Aksana K. Jones
    Doerthe Eckert
    Sven Mensing
    Shekman L. Wong
    Rod A. Humerickhouse
    Walid M. Awni
    Ahmed Hamed Salem
    Clinical Pharmacokinetics, 2017, 56 : 515 - 523
  • [48] Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens
    Serafin, Andrea
    Cellini, Alessandro
    Cavarretta, Chiara Adele
    Ruocco, Valeria
    Angotzi, Francesco
    Zatta, Ivan
    Frezzato, Federica
    Bonaldi, Laura
    Martines, Annalisa
    Pravato, Stefano
    Piazza, Francesco
    Trentin, Livio
    Visentin, Andrea
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (01) : 189 - 193
  • [49] EFFICACY OF VENETOCLAX plus OBINUTUZUMAB plus IBRUTINIB COMPARED TO ALTERNATIVE THERAPEUTIC OPTIONS IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (FIT POPULATION): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Stozek-Tutro, A.
    Reczek, M.
    Kawalec, P.
    VALUE IN HEALTH, 2023, 26 (12) : S46 - S46
  • [50] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB VERSUS IBRUTINIB IN HIGH-RISK PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS)
    Capra, M. E. Z.
    Pereira Pinto, R.
    Brito Filho, C.
    Travassos, A.
    VALUE IN HEALTH, 2021, 24 : S33 - S33
12345